NCT03334682View on ClinicalTrials.gov

Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

February 3, 2023

Study Completion Date

July 4, 2023

Conditions
Acne Vulgaris
Interventions
DRUG

spironolactone

Dispensation of spironolactone at each visit according to the arm description described above.

DRUG

Doxycycline

Dispensation of doxycycline then placebo, at each visit according to the arm description described above.

Trial Locations (9)

Unknown

Chru Brest, Brest

CHU Caen, Caen

CHU Grenoble, Grenoble

CH La Rochelle, La Rochelle

CH Le Mans, Le Mans

CHU de Nantes - Dermatologie, Nantes

CHU Poitiers, Poitiers

Cabinet du Dr Jean-Paul Claudel, Tours

CHRU Tours, Tours

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT03334682 - Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman. | Biotech Hunter | Biotech Hunter